Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P62873: Variant p.Ile80Asn

Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Gene: GNB1
Feedback?
Variant information Variant position: help 80 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Isoleucine (I) to Asparagine (N) at position 80 (I80N, p.Ile80Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MRD42; also found in patients with acute lymphoblastic T-cell leukemia; reduces interaction with GNAI2, GNAI3, GNA13 and GNA11; induces activation of PI3K-AKT-mTOR and MAPK pathways. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 80 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 340 The length of the canonical sequence.
Location on the sequence: help AMHWGTDSRLLVSASQDGKL I IWDSYTTNKVHAIPLRSSWV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 340 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Repeat 53 – 83 WD 1
Beta strand 78 – 83



Literature citations
Germline de novo mutations in GNB1 cause severe neurodevelopmental disability, hypotonia, and seizures.
Petrovski S.; Kuery S.; Myers C.T.; Anyane-Yeboa K.; Cogne B.; Bialer M.; Xia F.; Hemati P.; Riviello J.; Mehaffey M.; Besnard T.; Becraft E.; Wadley A.; Politi A.R.; Colombo S.; Zhu X.; Ren Z.; Andrews I.; Dudding-Byth T.; Schneider A.L.; Wallace G.; Rosen A.B.; Schelley S.; Enns G.M.; Corre P.; Dalton J.; Mercier S.; Latypova X.; Schmitt S.; Guzman E.; Moore C.; Bier L.; Heinzen E.L.; Karachunski P.; Shur N.; Grebe T.; Basinger A.; Nguyen J.M.; Bezieau S.; Wierenga K.; Bernstein J.A.; Scheffer I.E.; Rosenfeld J.A.; Mefford H.C.; Isidor B.; Goldstein D.B.;
Am. J. Hum. Genet. 98:1001-1010(2016)
Cited for: INVOLVEMENT IN MRD42; VARIANTS MRD42 GLU-76; GLY-76; SER-77; ARG-78; ASN-80; THR-80; PRO-95; VAL-101 AND THR-326; Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance.
Yoda A.; Adelmant G.; Tamburini J.; Chapuy B.; Shindoh N.; Yoda Y.; Weigert O.; Kopp N.; Wu S.C.; Kim S.S.; Liu H.; Tivey T.; Christie A.L.; Elpek K.G.; Card J.; Gritsman K.; Gotlib J.; Deininger M.W.; Makishima H.; Turley S.J.; Javidi-Sharifi N.; Maciejewski J.P.; Jaiswal S.; Ebert B.L.; Rodig S.J.; Tyner J.W.; Marto J.A.; Weinstock D.M.; Lane A.A.;
Nat. Med. 21:71-75(2015)
Cited for: CHARACTERIZATION OF VARIANTS MRD42 ASN-80 AND THR-80;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.